TCRX Tscan Therapeutics Inc
Company Analysis
Latest News
TScan's Blood Cancer Therapy Shows Early Promise, but Can a Sub-Dollar Stock Survive Long Enough to Prove It?
Shares of TScan Therapeutics jumped +9% to $0.94 after the company unveiled encouraging early results from its lead cancer therapy — an engineered immune-cell...
🟢 TCRX is trading 9% up today on positive Phase 1 data for TSC-101
TCRX is trading at $0.94 (+8.99%) after TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101 in hematologic...
TScan Announces Positive Phase 1 Data for TSC-101 in Heme Malignancies
TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101 in patients with hematologic (heme) malignancies. The...
🟢 Tscan Therapeutics Inc is trading 5.2% up today after presenting positive data from its ALLOHA™ Phase 1 study
• Tscan Therapeutics Inc. presented positive data today from Cohort C of its ALLOHA™ Phase 1 study, evaluating TSC-101 in patients with heme malignancies. • 11...
🟢 Tscan Therapeutics Inc is trading 5.9% up today as it recovers from yesterday's sharp drop
Tscan Therapeutics Inc is trading at $0.90, up 5.9%, as the stock bounces back from a significant 10.8% decline in the previous session. • The move appears to...
🔴 Tscan Therapeutics Inc makes sharp 10.8% drop
TCRX is trading at $0.85, down 10.8% versus the comparison close of $0.95 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 Tscan Therapeutics Inc is trading 5.6% down today on normal volatility and giveback of recent gains
Tscan Therapeutics Inc is trading 5.6% down today at $0.90 as the stock experiences normal volatility and a giveback of recent gains. • The decline follows a...
🟢 Tscan Therapeutics Inc is trading 4.5% up today on broad risk-on rally following U.S.–Iran peace deal
Tscan Therapeutics Inc is trading 4.5% up at $0.95 as part of a broad risk-on rally triggered by a tentative U.S.–Iran peace agreement. • The stock bounced...
🟢 Tscan Therapeutics Inc is trading 5.3% up today amid broad risk-on sentiment following a U.S.–Iran peace agreement
Tscan Therapeutics Inc is trading 5.3% up at $0.96 in pre-market action, tracking a broad risk-on tone in U.S. equity futures as markets react to geopolitical...